4P-Pharma, a Lille-based clinical-stage startup, raises €15m in Series B funding for drug regeneration model development.

4P-Pharma, a Lille-based clinical-stage startup, raises €15m in its second funding round, with participation from private investors. The funds will support its drug regeneration model for untreated serious diseases, enabling M&A and licensing-in opportunities. The company's goal is to bring first-class medicines to patients rapidly, leveraging drug candidates with reduced development times.